5AM Ventures Raises $200M for 3rd Life Science Venture Capital Fund
MENLO PARK, CA., December 7, 2009 -- 5AM Venture Management, LLC of Menlo Park, CA and Waltham, MA is pleased to announce the closing of 5AM Ventures III, L.P., a $200 million venture capital fund focused on early‐stage life science companies. The capital was raised from a broad range of current and new institutional investors including endowments, family offices, foundations, funds‐of‐funds and pension funds.
Formed by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands‐on approach to company building. 5AM portfolios are well diversified, including spinouts from established life science companies, innovative platform technologies
and companies developing near‐term products. 5AM will continue to focus on early‐stage life
science companies with the majority of the investments being made in the discovery and
development of novel therapeutics. A meaningful portion of the fund will also be invested in
companies developing diagnostics, materials, medical devices and reagents.
5AM’s investment team consists of Managing Partners John Diekman, Ph.D., Scott Rocklage,
Ph.D., and Andy Schwab; Venture Partners Mason Freeman, M.D., Richard Ulevitch, Ph.D. and
Jim Young, Ph.D.; Principals Mark Colella, Kevin Forrest, Ph.D. and Andrew McMillan, Ph.D. and
Associate Jennifer Ma, Ph.D. 5AM’s Finance & Administrative team is led by General Counsel &
COO Paul Stone, J.D. and Vice President, Finance, Jenny Lee.
About 5AM Ventures
Founded in 2002, 5AM Ventures is focused on actively investing in next‐generation life science
companies. With over $400 million under management, 5AM has invested in 27 early‐stage
companies and is currently investing 5AM Ventures III, LP. For more information, please visit
5AM Venture Management LLC
Andy Schwab, Managing Partner, +1‐650‐233‐8604